RBC Capital downgraded ResMed to Sector Perform from Outperform with a price target of $202, down from $273.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RMD:
- ResMed upgraded to Overweight from Neutral at JPMorgan
- ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
- ResMed price target lowered to $165 from $240 at Jefferies
- Brinker upgraded, Berkshire Hathaway downgraded: Wall Street’s top analyst calls
- ResMed downgraded to Peer Perform from Outperform at Wolfe Research